Spiegelberg Diana, Malmberg Christer, Tiblom Ehrsson Ylva, Laurell Göran
Department of Surgical Sciences, Uppsala University, 75185 Uppsala, Sweden.
Department of Immunology, Genetics and Pathology, Uppsala University, 75185 Uppsala, Sweden.
Cancers (Basel). 2022 Oct 21;14(20):5161. doi: 10.3390/cancers14205161.
This prospective study identifies high-risk groups for recurrence of head and neck cancer by BMI and circulating inflammatory response markers. Head and neck cancer patients from three Swedish hospitals were included ( = 272). Leukocyte and thrombocyte counts, CRP levels, and BMI were measured pre-treatment and post-treatment. Associations between the four factors and treatment failure (residual tumor, loco-regional failure, general failure/distant metastasis) were assessed using a Cox proportional hazards model adjusted for sex, age at the initial visit, smoking status, cancer stage, and hemoglobin count. CRP level was the only significant single variable, with an average increase in risk of recurrence of 74% ( = 0.018) for every doubling. The predictive power of a combined model using all variables was highest during the initial months after treatment, with AUC under the ROC curve 0.75 at the 0-3 month timepoints. Patients with elevated pre- and post-treatment CRP levels are at higher risk for recurrence of disease. Male patients with low post-treatment BMI, advanced stage, and high CRP at any time post treatment are at high risk for recurrence. The combined model may be useful for stratifying post-treatment patients into low and high-risk groups, to enable more detailed follow-up or additional treatment regimens.
这项前瞻性研究通过体重指数(BMI)和循环炎症反应标志物确定头颈癌复发的高危人群。纳入了来自瑞典三家医院的头颈癌患者(n = 272)。在治疗前和治疗后测量白细胞和血小板计数、CRP水平以及BMI。使用Cox比例风险模型评估这四个因素与治疗失败(残留肿瘤、局部区域失败、全身失败/远处转移)之间的关联,并对性别、初次就诊年龄、吸烟状况、癌症分期和血红蛋白计数进行校正。CRP水平是唯一显著的单一变量,每增加一倍,复发风险平均增加74%(P = 0.018)。使用所有变量的联合模型在治疗后的最初几个月预测能力最高,在0 - 3个月时间点,ROC曲线下面积(AUC)为0.75。治疗前和治疗后CRP水平升高的患者疾病复发风险更高。治疗后BMI低、分期晚且治疗后任何时间CRP高的男性患者复发风险高。联合模型可能有助于将治疗后的患者分为低风险和高风险组,以便进行更详细的随访或采用额外的治疗方案。